Friday 6 November 2026 Export IBRX’s income statement to Excel — free account

ImmunityBio, Inc.

IBRX Healthcare Biotechnology

ImmunityBio, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $113.3 million, up 668.3% from fiscal 2024.

Revenue: +93.9%
EPS: −120.0%
Free cash flow: +13.4%
Total debt: +57.4%

Quarter to June 2026, against a year earlier

Revenue growth 3 yrs

8.51 0.50 +6.24%

Follow IBRX

Alert me

Market cap: $8.5B
P/E: 0.0×
Fwd P/E: −8.7×
Dividend yield: —
F-score: 4/9
Altman Z: −10.16
Beneish M: 4.57
Dividend safety: n/a

Overview Business Profile Earnings & Analysis Segments Valuation Filings

ImmunityBio, Inc. (IBRX) P/B ratio

Alert me on P/B ratio

ImmunityBio, Inc. has no meaningful P/B ratio: its trailing twelve-month book value is negative. Over the past ten years it has ranged from 0.0× (November 2026) to 45.2× (December 2020) — the current reading is the lowest in ten years.

Embed this chart

Code for your page

<iframe src="https://stockrow.com/embed/IBRX/pb-ratio" width="100%" height="360" style="border:0" loading="lazy" title="ImmunityBio, Inc. P/B ratio, 10 years"></iframe>
<p style="font-size:12px">Source: <a href="https://stockrow.com/IBRX/metrics/pb-ratio">ImmunityBio, Inc. (IBRX) P/B ratio — stockrow.com</a></p>

Period	P/B ratio	Change
FY2025	0.0×	—
FY2024	0.0×	—
FY2023	0.0×	—
FY2022	0.0×	—
FY2021	0.0×	—
FY2020	0.0×	—
FY2019	11.5×	1,729.92%
FY2018	0.6×	(61.02%)
FY2017	1.6×	(2.33%)
FY2016	1.7×	(52.57%)

Period	P/B ratio	Change
Jun 2026	0.0×	—
Mar 2026	0.0×	—
Dec 2025	0.0×	—
Sep 2025	0.0×	—
42 more quarters	Free account

Against its own ten years

Low 0.0× High 45.2×

Ten-year median 0.0×

Current reading's percentile 50

Company	P/B ratio
CYTK Cytokinetics, Incorporated compare	n/m
IBRX ImmunityBio, Inc.	n/m
KRYS Krystal Biotech, Inc. compare	6.2×
SYRE Spyre Therapeutics, Inc. compare	9.5×
PTGX Protagonist Therapeutics, Inc. compare	10.6×
CAI Caris Life Sciences,�Inc. compare	12.7×
TGTX TG Therapeutics, Inc. compare	13.6×
TWST Twist Bioscience Corporation compare	17.1×
MDGL Madrigal Pharmaceuticals, Inc. compare	18.7×
Biotechnology industry median	2.0×
Healthcare sector median	2.3×
Market median	1.7×

What P/B ratio is

Price to Book Value tells an investor how much the market pays for a company’s shares relative to the accounting net worth that belongs to common shareholders.

Stock Price ÷ (Common Equity (Total) (latest quarter) ÷ Shares (Basic, Weighted) (latest quarter))

The full definition of P/B ratio →

ImmunityBio, Inc. (IBRX) P/B ratio

P/B ratio, daily

Annual newest first

Quarterly newest first

Against its own ten years

P/B ratio against peers

What P/B ratio is

More on IBRX

P/B ratio, daily

Annual newest first

Quarterly newest first

Against its own ten years

P/B ratio against peers

What P/B ratio is

More on IBRX

Stockrow Weekly